We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Oxurion NV is a leading ophthalmology biopharmaceutical company developing treatments to preserve vision for patients with diseases affecting the back of the eye. It has engineered a diverse portfolio of best-in-class disease-modifying drug candidates, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide. Oxurion’s clinical pipeline consists of THR-317, an anti- PlGF antibody in phase 2 for the treatment of DME, and in a phase 2 for MacTel 1; THR-149, a plasma kallikrein inhibitor for the treatment of DME; and THR-687, a pan-RGD integrin antagonist for the treatment of DR, DME, and wet AMD.